12 results
·
20ms
·
Sources: EU EUDAMED, US FDA
ATEC IOM Accessory Instruments
FDA 510(k)
FDA Class 2
·Ear, Nose, Throat
Oticon
FDA UDI
Oticon A/S·05707131331403·OPN 2, KIT 13 2.4G NFM L C001
SimpliCore
FDA UDI
Kerr Corporation·00195062153464·Kerr SimpliCore Obturator for ZenFlex ONE Size ...
TRAUSON GENERAL SPINAL SYSTEM (GSS)
FDA 510(k)
FDA Class 2
·Orthopedic
AUDIT MICROCV CARDIAC MARKERS LINEARITY SET
FDA 510(k)
FDA Class 1
·Clinical Chemistry
DEXCOM G7 CONTINUOUS GLUCOSE MONITORING SYSTEM
FDA Adverse Event
Malfunction
·DEXCOM, INC.·Product code QBJ·July 14, 2025
LINER: MPACT FLAT PE HC LINER 36/G
FDA Adverse Event
Injury
·MEDACTA INTERNATIONAL SA·Product code LPH·September 15, 2020
PARADIGM REAL-TIME REVEL INSULIN INFUSION PUMP
FDA Adverse Event
Malfunction
·MEDTRONIC PUERTO RICO OPERATIONS CO.·Product code OYC·October 17, 2014
S-ROM M HEAD 36MM +0
FDA Adverse Event
Injury
·DEPUY ORTHOPAEDICS INC US·Product code JDI·June 21, 2013
*
FDA Adverse Event
SIERRA SCIENTIFIC INSTRUMENTS·Product code FFX·July 15, 2011
St. Jude Medical CONFIRM Rx Insertable Cardiac Monitor, Sterile EO, Model #: DM3500 The Confirm Rx ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
FDA Enforcement
Class II
·Terminated·St Jude Medical Inc.·July 11, 2018
Merlin PCS Programmer software model 3330, used with Confirm Rx Insertable Cardiac Monitor (ICM), Model DM3500, Sterile. The firm name on the label of the ICM is St. Jude Medical Cardiac Rhythm Management Division, Sylmar, CA. - Product Usage: The Confirm Rx insertable cardiac monitor is designed to detect arrhythmias and wirelessly transmit data to the Merlin.net Patient Care Network. The Confirm Rx ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
FDA Enforcement
Class II
·Terminated·St Jude Medical, Cardiac Rhythm Management Division·January 22, 2020